Commentary on “Integrative clinical genomics of advanced prostate cancer”. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215–1228.

Autor: Freedland, Stephen J., Aronson, William J.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations August 2017 35(8):535-535

Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.

Autor: Yoshimi A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lin KT; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA., Wiseman DH; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.; Division of Cancer Sciences, The University of Manchester, Manchester, UK., Rahman MA; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA., Pastore A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wang B; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lee SC; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Micol JB; Gustave Roussy, Université Paris-Saclay, Villejuif, France., Zhang XJ; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Botton S; Gustave Roussy, Université Paris-Saclay, Villejuif, France., Penard-Lacronique V; Gustave Roussy, Université Paris-Saclay, Villejuif, France., Stein EM; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cho H; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Miles RE; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Inoue D; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Albrecht TR; Department of Biochemistry & Molecular Biology, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA., Somervaille TCP; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK., Batta K; Division of Cancer Sciences, The University of Manchester, Manchester, UK., Amaral F; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK., Simeoni F; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK., Wilks DP; Manchester Cancer Research Centre Biobank, The University of Manchester, Manchester, UK., Cargo C; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK., Intlekofer AM; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Levine RL; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Dvinge H; Department of Biomolecular Chemistry, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA., Bradley RK; Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Wagner EJ; Department of Biochemistry & Molecular Biology, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA., Krainer AR; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA., Abdel-Wahab O; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. abdelwao@mskcc.org.; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. abdelwao@mskcc.org.

Publikováno v: Nature [Nature] 2019 Oct; Vol. 574 (7777), pp. 273-277. Date of Electronic Publication: 2019 Oct 02.

Evaluation of Spliceosome Protein SmD2 as a Potential Target for Cancer Therapy.

Autor: Li, Jing^1,2 (AUTHOR), Li, Peiyu^1,2 (AUTHOR), Brachtlova, Tereza^1,2,3,4 (AUTHOR), van der Meulen-Muileman, Ida H.¹ (AUTHOR), Dekker, Henk¹ (AUTHOR), Kumar, Vishal S.¹ (AUTHOR), Fransen, Marieke^2,4,5 (AUTHOR), Bahce, Idris^4,5,6 (AUTHOR), Felley-Bosco, Emanuela⁷ (AUTHOR), van Beusechem, Victor W.^1,2,3,4 (AUTHOR) vw.vanbeusechem@amsterdamumc.nl

Publikováno v: International Journal of Molecular Sciences. Dec2024, Vol. 25 Issue 23, p13131. 20p.

miR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer.

Autor: Ouyang, Bin¹ (AUTHOR) ouyangb@ucmail.uc.edu, Bi, Mingjun¹ (AUTHOR) bimn@ucmail.uc.edu, Jadhao, Mahendra¹ (AUTHOR) jadhaomg@ucmail.uc.edu, Bick, Gregory¹ (AUTHOR) bickgp@ucmail.uc.edu, Zhang, Xiaoting^1,2 (AUTHOR) zhangxt@ucmail.uc.edu

Publikováno v: Cancers. Dec2024, Vol. 16 Issue 23, p3992. 18p.

miR-574-5p in epigenetic regulation and Toll-like receptor signaling.

Autor: Yang, James Y.^1,2,3 (AUTHOR) jamesyang@hsc.ecnu.edu.cn

Publikováno v: Cell Communication & Signaling. 11/26/2024, Vol. 22 Issue 1, p1-31. 31p.